UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 193,588 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 10.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,116,573 shares of the company's stock after purchasing an additional 193,588 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.75% of 10x Genomics worth $30,394,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in TXG. Signaturefd LLC lifted its stake in shares of 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after acquiring an additional 1,452 shares during the period. Blue Trust Inc. lifted its position in 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after purchasing an additional 1,299 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in 10x Genomics in the fourth quarter worth approximately $52,000. SRS Capital Advisors Inc. lifted its position in 10x Genomics by 817.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock worth $70,000 after purchasing an additional 4,324 shares during the period. Finally, KBC Group NV lifted its position in 10x Genomics by 57.3% in the fourth quarter. KBC Group NV now owns 5,072 shares of the company's stock worth $73,000 after purchasing an additional 1,847 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TXG has been the subject of several research analyst reports. Leerink Partners lowered 10x Genomics from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $25.00 to $12.00 in a report on Thursday, February 13th. Canaccord Genuity Group cut their price target on shares of 10x Genomics from $18.00 to $15.00 and set a "buy" rating for the company in a report on Monday, May 12th. The Goldman Sachs Group cut their price target on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating for the company in a report on Monday, May 12th. Citigroup cut their price target on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Finally, Barclays cut their target price on shares of 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, 10x Genomics presently has an average rating of "Hold" and an average price target of $15.81.

Insider Activity at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 4,044 shares of the company's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $33,565.20. Following the sale, the chief financial officer now directly owns 331,588 shares of the company's stock, valued at approximately $2,752,180.40. This represents a 1.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 7,485 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total transaction of $62,125.50. Following the sale, the insider now directly owns 448,374 shares of the company's stock, valued at approximately $3,721,504.20. The trade was a 1.64% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,872 shares of company stock worth $173,238 over the last three months. Company insiders own 9.39% of the company's stock.

10x Genomics Stock Up 1.6%

Shares of NASDAQ:TXG traded up $0.15 during trading on Friday, reaching $9.49. The stock had a trading volume of 4,649,181 shares, compared to its average volume of 2,426,523. 10x Genomics, Inc. has a 52 week low of $6.78 and a 52 week high of $24.76. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -6.24 and a beta of 1.94. The stock has a fifty day simple moving average of $8.46 and a two-hundred day simple moving average of $11.82.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The company had revenue of $154.88 million for the quarter, compared to the consensus estimate of $131.91 million. During the same period in the previous year, the business posted ($0.50) EPS. The company's revenue for the quarter was down 2.3% on a year-over-year basis. On average, analysts forecast that 10x Genomics, Inc. will post -1.43 EPS for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.